Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NGM438 |
Synonyms | |
Therapy Description |
NGM438 is a monoclonal anti-LAIR1 antibody that blocks collagen-induced immune suppression, which potentially leads to increased sensitivity to immune checkpoint inhibitors (Cancer Res 2022;82(12_Suppl):Abstract nr LB219). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NGM438 | NGM-438|NGM 438 | NGM438 is a monoclonal anti-LAIR1 antibody that blocks collagen-induced immune suppression, which potentially leads to increased sensitivity to immune checkpoint inhibitors (Cancer Res 2022;82(12_Suppl):Abstract nr LB219). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05311618 | Phase I | NGM438 NGM438 + Pembrolizumab | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | 0 |